Ed Esplin, Clinical Geneticist and Medical Officer of Invitae, shared a post on X about a recent article by Tin-Yun Tang et al, published in Cancer Discovery:
“Germline Mutations as Cancer Drug Targets
Given the rapid…progress…in…molecular diagnoses and associated treatments, universal germline testing for every patient diagnosed with cancer should be considered.
…early successes and high prevalence of pathogenic germline mutations provide the rationale for universal germline testing to maximize the therapeutic opportunities available to patients with cancer.”
Title: Germline Mutations as Cancer Drug Targets
Authors: Tin-Yun Tang, Karen Colbert Maresso, Joanne Ngeow, Eduardo Vilar, Timothy A. Yap
Read the Full Article on Cancer Discovery
More posts featuring Ed Esplin.
